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Elevation of brain glucose and 
polyol-pathway intermediates 
with accompanying brain-copper 
deficiency in patients with 
Alzheimer’s disease: metabolic 
basis for dementia
Jingshu Xu1,2,3, Paul Begley3, Stephanie J. Church3, Stefano Patassini1,2,3, Selina McHarg3, 
Nina Kureishy3, Katherine A. Hollywood3, Henry J. Waldvogel2, Hong Liu1, Shaoping Zhang1, 
Wanchang Lin3, Karl Herholz4, Clinton Turner5, Beth J. Synek2,5, Maurice A. Curtis2, 
Jack Rivers-Auty4, Catherine B. Lawrence4, Katherine A. B. Kellett4, Nigel M. Hooper4, 
Emma R. L. C. Vardy6, Donghai Wu7, Richard D. Unwin3, Richard L. M. Faull2,*, 
Andrew W. Dowsey3,* & Garth J. S. Cooper1,2,3,*
Impairment of brain-glucose uptake and brain-copper regulation occurs in Alzheimer’s disease (AD). 
Here we sought to further elucidate the processes that cause neurodegeneration in AD by measuring 
levels of metabolites and metals in brain regions that undergo different degrees of damage. We 
employed mass spectrometry (MS) to measure metabolites and metals in seven post-mortem brain 
regions of nine AD patients and nine controls, and plasma-glucose and plasma-copper levels in an 
ante-mortem case-control study. Glucose, sorbitol and fructose were markedly elevated in all AD brain 
regions, whereas copper was correspondingly deficient throughout (all P < 0.0001). In the ante-mortem 
case-control study, by contrast, plasma-glucose and plasma-copper levels did not differ between 
patients and controls. There were pervasive defects in regulation of glucose and copper in AD brain 
but no evidence for corresponding systemic abnormalities in plasma. Elevation of brain glucose and 
deficient brain copper potentially contribute to the pathogenesis of neurodegeneration in AD.
“Alzheimer’s disease” (AD) is the predominant cause of ageing-related dementia1 and refers to a constellation 
of cognitive and behavioural changes that are typical for patients who have substantial amounts of its hallmark 
pathological lesions in their brain2. AD may occur through interplay of environmental, genetic, and metabolic 
factors3,4, but some brain regions are impacted more severely than others, consistent with operation of a specific 
disease mechanism5,6. The pathophysiological process of AD is thought to begin many years before the diagnosis 
of AD-related dementia7,8, and sporadic AD accounts for the vast majority of cases2. AD is a non-communicable 
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disease which displays several pathogenic mechanisms in brain , including: Aβ -amyloid deposition9; neurofibril-
lary tangles comprising tau protein2,8; impaired cerebral glucose metabolism (‘hypometabolism’) with insulin 
resistance and defective carbohydrate regulation8,10; oxidative stress and inflammation4,11; cerebrovascular amy-
loid angiopathy (CAA)12; enhanced advanced glycation end-product (AGE) formation9; and defective copper 
regulation13,14. Risk of sporadic AD has also been linked to presence of type-2 diabetes (T2D) in epidemiological 
studies15,16.
Glucose uptake17,18 and regional cerebral perfusion6 are impaired in AD, particularly in severely-damaged 
brain regions5,19, and progressive reductions in glucose-uptake may occur years before clinically-evident demen-
tia19: however, the molecular basis for these defects is uncertain. Impaired brain-glucose regulation has been ten-
tatively attributed to a functional defect of glucose transporter (GLUT)-mediated glucose uptake20, but neuronal 
loss may be responsible for some of this effect, and there is ongoing argument concerning the contribution of this 
mechanism to defective brain-glucose uptake and neurodegeneration.
Here we analyzed post-mortem tissue from seven brain regions of patients with AD and controls in whom 
clinical dementia had been excluded and who had no ante-mortem evidence for neurodegeneration or T2D. 
Diabetes was excluded in this post-mortem study on the basis of a negative history and lack of any biochemical 
evidence of hyperglycemia but not by systematic ante-mortem glucose-tolerance testing: it is therefore possible, 
albeit unlikely, that one or more patients had undiagnosed mild T2D or prediabetes. Elevated glucose levels have 
previously been linked to altered tissue-copper regulation in the context of diabetes21. Furthermore, in AD, some 
brain regions are more severely damaged than others22,23. Therefore, we measured tissue levels of metabolites and 
trace metals24,25 in seven human brain-regions in patients and controls matched for age and gender: three of these 
undergo severe neuronal damage in AD (hippocampus, entorhinal cortex and middle temporal gyrus); three are 
less affected (cingulate gyrus, sensory cortex and motor cortex); and one (cerebellum) is relatively spared5,6,22. 
We also measured levels of brain metabolites and copper in (i) post-mortem whole-brain tissue of diabetic and 
control rats, to probe potential effects of post-mortem delay (PMD) on metabolite levels and contrast effects of AD 
with those of diabetes in an animal model; and (ii) metabolites and metal levels in brains from a triple-transgenic 
mutant model of familial AD (fAD) and controls26. Finally, we measured fasting-plasma glucose (FPG), hemo-
globin A1c (HbA1c), and fasting-plasma copper in AD-patients and controls from a clinical case-control study, 
to ascertain whether patients might show evidence of elevated systemic glucose consistent with diabetes or lesser 
degrees of hyperglycemia, or signs of impaired systemic copper metabolism.
Results
Post-mortem study of AD brain: group characteristics. All participants in this study were from New 
Zealand and were matched for age, gender and PMD (Tables 1 and 2). Median (range) brain-weight was 1062 
(831–1355) g in cases and 1260 (1094–1461; P = 0.005) in controls (Tables 1 and 2): the ~16% decline in brain-
weight in AD is consistent with histological severity22. The case-control matching and short PMD support the 
quality of these data (Tables 1 and 2). Cases were diagnosed with AD by clinical27, CERAD28 and Braak criteria22: 
patients had late-onset/sporadic AD and none had findings consistent with early-onset AD, fAD, or T2D.
Glucose levels in AD brain. Levels of glucose were elevated in all brain regions of AD-patients (Table 3, 
Figs 1–3). Mean (± 95% CI) elevations in glucose varied from 5.2-fold (1.4–18.6) in cerebellum to 16.4-fold (5.2–51.2) 
in middle temporal gyrus (Figs 1 and 2a). There was evidence for differences in glucose elevations between dif-
ferent brain regions in AD where levels tended to be higher in more severely affected regions such as the middle 
temporal gyrus (Table 3; Figs 1 and 2a). Elevated glucose levels can damage proteins and lipids through chemical 
attack via the aldehyde group, forming AGEs in diabetic tissues9,29. Our data indicate that potential exists for sim-
ilar glucose-driven damage mechanisms to occur in AD brain, consistent with co-localization there of AGEs with 
Aβ -containing plaque9. Variation in PMD did not affect glucose values here (data not shown).
Sorbitol levels in AD brain. Sorbitol, formed from glucose, is the first metabolite in the polyol pathway, 
which usually accounts for a few percent at most of glucose utilization under normal conditions30. Here, sorbitol 
was elevated in all AD brain regions: mean (± 95% CI) fold-elevations ranged from 3.0 (1.4–6.6) in motor cortex 
to 4.3 (2.0–9.1) in entorhinal cortex (Figs 1 and 2; Table 3). Variation in sorbitol levels was less than for glucose 
Variable Control Alzheimer’s disease
Number 9 9
Age 70.1 (6.7) 70.3 (7.1)
Male sex, n (%) 5 (55.6) 5 (55.6)
PMD (h) 9 (5.5–13.0) 7 (4.0–12.0)
Brain-weight (g) 1260 (1094–1461) 1062 (831–1355)* 
Plaques, n (%) 1 (11) 9 (100)* * 
Tangles, n (%) 1 (11) 9 (100)* * 
Table 1.  Case-control study of post-mortem human brain in Alzheimer’s disease: group characteristics. 
Values are: age, mean (SD); PMD and brain-weights, median (range): * P = 0.005, * * P < 0.0001 compared with 
corresponding Control value; all other differences are non-significant.
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and there was no evidence for inter-regional differences, possibly reflecting sorbitol formation from glucose as the 
rate-limiting step in the polyol pathway. Variation in PMD did not affect sorbitol levels.
Fructose levels in AD brain. Fructose is the second metabolite in the polyol pathway30. Fructose may be 
even more reactive in AGE-mediated damage mechanisms than glucose, and levels of the two are similar in AD 
brain. Here, brain-fructose levels were elevated in all cases, consistent with the findings for glucose and sorbitol 
(Figs 1 and 2a; Table 3). Elevations in brain fructose showed less variation than glucose, consistent with sorbi-
tol: fold-elevations were between 3.9 (1.7–9.2) in cingulate gyrus and 5.7 (2.6–12.9) in middle temporal gyrus. 
Inter-regional differences were not significant and variation in PMD did not affect fructose levels.
Inter-regional comparisons of metabolite levels in human brain. Mean elevations in glucose 
fold-change, 9.5 (3.0–30.4) were significantly higher across all regions in AD brain than those for sorbitol and fruc-
tose (P = 0.0002). Values for sorbitol, 3.6 (1.7–7.8), and fructose, 5.1 (2.1–12.2) did not differ significantly across 
regions. Mean values of all three metabolites were substantively elevated in all AD brain regions (Figs 1 and 2): 
these elevations were widespread in AD, consistent with a global defect.
Post-mortem brain metabolites in a patient with preclinical AD. Elevated brain levels of glu-
cose, sorbitol and fructose were present in one control patient, a 76 year-old female (Code H241) who had 
no ante-mortem clinical evidence for brain disease or dementia, but had preclinical AD characterized by low 
brain-weight (1,094 g) and positive post-mortem histology (Braak Stage II; ABC score2 of A3, B1, C1; black squares 
in Fig. 1) consistent with “AD neuropathologic change”2. This finding indicates that substantive disturbance of 
brain glucose and polyol pathway regulation may antedate the onset of clinical dementia, possibly by a consider-
able period.
Copper levels in AD brain. Mean (± 95% CI) brain-copper levels summed across all seven regions were 
256 (232–279) μ mol/dry kg in AD and 406 (363–449) μ mol/dry kg in controls (P = 1.6 × 10−8): there was thus an 
overall decrease of ~40% in brain-copper levels in AD. Mean brain-copper levels tended to be lower in AD than 
controls in all brain regions examined (Fig. 3). In addition, there was moderate evidence for a trend in copper lev-
els to be inversely proportional to tissue-glucose values in AD-patients (P = 0.021; restricted iterative generalized 
least squares31) but not in controls.
Levels of tissue metabolites and copper in rodent brain. We did not have access to post-mortem 
brain from diabetic patients with dementia suitable for this study. Instead, we measured levels of metabolites and 
trace metals in whole brains from male rats with streptozotocin-induced diabetes (a model of severe T1D)21 and 
No Code Group Age/Sex
Ante-mortem assessment of 
brain disease/mental state Cause of death
Braak Stage 
(Amyloid load) PMD (h)
Brain 
Wt (g)
1 H155 Control 61/M No brain disease or dementia Ischemic heart disease 0 (0) 7.0 1258
2 H121 Control 64/F No brain disease or dementia Pulmonary embolism 0 (0) 5.5 1260
3 H132 Control 63/F No brain disease or dementia Ruptured aorta 0 (0) 12.0 1280
4 H122 Control 72/F No brain disease or dementia Emphysema 0 (0) 9.0 1230
5 H204 Control 66/M No brain disease or dementia Ischemic heart disease 0 (0) 9.0 1461
6 H241 Control 76/F No brain disease or dementia Metastatic carcinoma II (A3, B1, C1) 12.0 1094
7 H164 Control 73/M No brain disease or dementia Ischemic heart disease 0 (0) 13.0 1315
8 H123 Control 78/M No brain disease or dementia Ruptured aortic aneurysm 0 (0) 7.5 1260
9 H150 Control 78/M No brain disease or dementia Ruptured MI 0 (0) 12.0 1416
10 AZ42 AD 60/M Alzheimer’s dementia Alzheimer’s disease VI (3/3) 7.0 1020
11 AZ71 AD 62/F Alzheimer’s dementia Alzheimer’s disease VI (3/3) 6.0 831
12 AZ48 AD 63/F Alzheimer’s dementia Bronchopneumonia VI (2/3) 7.0 1080
13 AZ72 AD 70/F Alzheimer’s dementia Lung cancer V (3/3) 7.0 1044
14 AZ90 AD 73/M Alzheimer’s dementia GI hemorrhage IV (3/3) 4.0 1287
15 AZ96 AD 74/F Alzheimer’s dementia Metastatic cancer V (3/3) 8.5 1062
16 AZ39 AD 74/M Alzheimer’s dementia Pseudomonas bacteremia VI (2/3) 12.0 1355
17 AZ80 AD 77/M Alzheimer’s dementia Myocardial infarction VI (3/3) 4.5 1180
18 AZ38 AD 80/M Alzheimer’s dementia Bronchopneumonia/ pulmonary oedema V (3/3) 5.5 1039
Table 2.  Individual patient characteristics. Abbreviations: GI, gastrointestinal; MI, myocardial infarction; 
PMD, post-mortem delay; wt, weight. Cause of death was determined by post-mortem examination, and 
brain pathology and Braak Stage were determined by specialist neuropathological examination. All AD cases 
had ‘Age-Related Plaque’ scores of “C”. Causes of death were the primary causes listed on the death certificate. 
Patient H241 had post-mortem signs consistent with AD and was therefore diagnosed with preclinical disease: 
the corresponding data have been retained in the main analysis presented in the manuscript, and removed from 
the control group for the secondary analysis. Control patient H241 (preclinical AD) was described as A3, B1, C1 
using the ‘ABC’ criteria for AD neuropathologic change that incorporates histopathological assessments of Aβ 
deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C)2.
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whole mouse brains from a model of AD (13–14-month-old male triple-transgenic mice)26, by applying the same 
methods we used for analysis of human brain. Diabetic-rat brain displayed marked elevations in glucose, sorb-
itol, and fructose, similar to those in human AD brain (Suppl. Table S1; Fig. 2b; all P < 0.0001). Thus, elevations 
in post-mortem human AD brain tissue were similar to those in rat-brain snap-frozen within ~1 minute after 
death. By contrast, there was no significant difference in brain-copper levels between diabetic and control rats: 
mean (± 95% CI) copper values were 209.0 (189.8–228.1) μ mol/dry-kg in diabetic rats and 188.4 (147.1–229.8) 
μ mol/dry-kg in controls.
In the triple-transgenic model of AD26, brain-glucose levels were below the limits of detection (~1–5 μ mol/kg) 
in both experimental groups; brain-fructose levels were lower in transgenic mice than controls (P = 0.0005); sorb-
itol levels trended lower in transgenic mice but differences were not significant; and copper values did not differ 
between transgenic mice and controls (data not shown).
Case-control study of plasma glucose and plasma-copper levels in patients with AD. 
Participants in this case-control study were matched for gender and age (see Suppl. Table S2). Consistent with 
expectation, measured cognitive function scores (MMSE) in the AD group were significantly lower than those 
of controls whereas the ApoE4 allele was more prevalent. FPG and serum HbA1c levels were equivalent between 
groups so there was no evidence for elevated rates of undiagnosed T2D, impaired glucose tolerance (IGT) or 
impaired fasting glucose (IFG) in these British patients with late-onset AD. Fasting plasma-copper levels did not 
differ significantly between the AD group and controls (see Suppl. Table S2).
Discussion
Glucose is the obligatory energy-generating substrate in the brain32, and impaired brain-glucose uptake and uti-
lization is a key metabolic defect in AD33: this phenomenon is generally worse in brain regions with greater his-
tological3,34, functional19 and molecular4 evidence of damage, consistent with the operation of a specific disease 
process17,19. Transport of glucose across the plasma membrane of mammalian cells is the first rate-limiting step 
for glucose metabolism and is mediated by facilitative GLUT proteins35. One potential explanation for decreased 
brain-glucose uptake could be that of impaired GLUT activity, leading to consequent cerebral ‘hypometabolism’. 
Consistently, lowered levels of GLUT1, the main glucose transporter in the blood-brain barrier (BBB), have been 
reported in several studies of AD20,36–39; many GLUT-related changes in AD pathogenesis may occur before the 
onset of neuronal dysfunction40. A reduction of GLUTs at the BBB that occurs before the onset of the main patho-
physiological changes and symptoms of AD could contribute to pathogenesis39. However, direct measurements 
of glucose concentrations in AD brain tissue have hitherto been lacking.
Unexpectedly, we found here that glucose levels in AD were markedly elevated rather than decreased in all 
seven brain regions of these patients with late-onset AD: therefore, diminished cerebral GLUT activity is unlikely 
Metabolite Brain-region Estimate
Lower 
Bound
Upper 
Bound P-value
BH FDR 
Q-value
Glucose
Cerebellum 5.2 1.4 18.6 0.015 0.015
Entorhinal cortex 7.4 2.4 23.2 0.0028 0.0041
Cingulate gyrus 8.0 2.4 26.1 0.0023 0.0037
Hippocampus 8.9 2.9 27.4 0.0016 0.0030
Sensory cortex 9.2 3.0 28.8 0.0014 0.0029
Motor cortex 11.8 3.7 37.7 0.0006 0.0019
Middle temporal gyrus 16.4 5.2 51.2 0.0002 0.0019
Sorbitol
Cerebellum 3.7 1.6 8.6 0.0036 0.0044
Entorhinal cortex 4.3 2.0 9.1 0.0006 0.0019
Cingulate gyrus 3.1 1.5 6.5 0.0048 0.0053
Hippocampus 4.1 1.9 8.5 0.0009 0.0021
Sensory cortex 4.1 1.9 8.6 0.0009 0.0021
Motor cortex 3.0 1.4 6.6 0.0090 0.0094
Middle temporal gyrus 3.3 1.5 6.9 0.0039 0.0046
Fructose
Cerebellum 5.3 2.0 14.4 0.0018 0.0031
Entorhinal cortex 5.7 2.4 13.5 0.0004 0.0019
Cingulate gyrus 3.9 1.7 9.2 0.0030 0.0041
Hippocampus 5.5 2.3 12.9 0.0005 0.0019
Sensory cortex 5.4 2.4 12.4 0.0004 0.0019
Motor cortex 4.2 1.7 10.2 0.0032 0.0041
Middle temporal gyrus 5.7 2.6 12.9 0.0003 0.0019
Table 3.  Study of post-mortem human brain: relative fold-changes in glucose, sorbitol and fructose in 
seven brain regions from nine Alzheimer’s cases and nine controls. Estimates and their lower and upper 
bounds were derived by Bayesian modelling. This table incorporates values from n = 9 patients with clinical 
diagnoses of AD and n = 9 matched asymptomatic controls. Abbreviation: ‘BH FDR Q-value’ is the Benjamini-
Hochberg False- Discovery Rate-adjusted P-value.
www.nature.com/scientificreports/
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to play an initiating role in decreased glucose uptake in AD. Rather, these data indicate that lower brain-GLUT/
glucose-uptake rates in AD probably occur in response to elevated brain-glucose levels; consistently, there is sub-
stantive evidence that elevated cellular glucose can mediate down-regulation of GLUT1 expression and func-
tion41,42. Elevated brain-glucose levels may therefore antedate the occurrence of GLUT down-regulation at the 
Figure 1. Log2-transformed concentrations of glucose, sorbitol and fructose in post-mortem tissue from 
seven brain regions of nine patients with AD and nine controls. Individual values are shown for each region. 
At the right-hand side are detailed the identity, sex, age, brain-weight, and PMD of each participant, along 
with the histopathological diagnosis. One control (Case 15: F76, brain wt 1094 g; black squares) with higher 
metabolite concentrations than other controls had preclinical AD (Braak Stage II).
www.nature.com/scientificreports/
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BBB in the pathogenesis of AD. The presence of elevated brain-glucose levels in AD accords with impaired intra-
cellular glucose utilization through glycolysis and the tricarboxylic acid (TCA) cycle: consistently, there is sub-
stantive evidence for defects in AD of TCA-related mitochondrial enzymes including the pyruvate dehydrogenase 
complex, the α -ketoglutarate dehydrogenase complex, and cytochrome c oxidase/complex IV43.
Here, marked elevations in levels of sorbitol and fructose were also present in all AD brain regions. These 
metabolites are produced from glucose via the polyol pathway in neurons and astrocytes44. The proportion of 
cortical oxidative metabolism attributable to astrocytes, ~30%, roughly corresponds to their volume fraction, 
indicating that astrocytes and neurons have similar fuel oxidation rates45, so both cell-types could contribute 
to this effect, in proportions depending on the relative distribution of polyol-pathway intermediates in the two.
Brain-glucose levels were lower in cerebellum than other regions whereas elevations in sorbitol and fructose 
were similar in all regions studied (Fig. 2). Glucose levels trended higher in regions more prone to tissue-damage 
in AD, consistent with insufficient clearance via glycolysis with consequent up-regulation of the alternative polyol 
pathway29. The human brain comprises similar numbers of neurons and non-neuronal cells46: both make substan-
tive contributions to functional in vivo indices of energy metabolism47, although non-neuronal cells have more 
prominent gluconeogenesis and glycogenesis48,49. It will therefore be important to determine whether the eleva-
tion of glucose and polyol-pathway intermediates in AD is caused by metabolic defects in neurons, glia, or both.
Our measurements of FPG and HbA1c50 in this group of patients with AD provide no evidence for increased 
prevalence of undiagnosed T2D, IGT or IFG (see Suppl. Table S2): therefore, it is unlikely that dementia in these 
patients occurred as a result of systemic disorders of glucose metabolism such as diabetes or IGT. Rather, our 
findings indicate that defective glucose metabolism in AD may occur only in a restricted location, the brain. Our 
Figure 2. Probability density distributions of fold-changes from controls to cases in glucose, sorbitol and 
fructose measured in brain tissue from (a) each of seven brain regions from patients with AD (n = 9) and 
controls (n = 9), and (b) whole brain homogenates from diabetic (n = 7) and control (n = 7) rats. Distributions 
were derived by Bayesian modeling and illustrate the plausible ranges (posterior distributions) of inferred 
fold changes for each region and metabolite. This analysis complements the results of a mixed-effects model 
assessment of the fold-change between AD cases and controls for measurements of metabolites in each brain 
region. Posterior means (solid lines) and 95% credible intervals (dashed lines) are shown, along with the ‘no fold 
change’ value (solid black line). (b) Shown are results of an equivalent simulation of data from a metabolomic 
study of ex-vivo whole-brain tissue from diabetic rats and controls. Data were log2-transformed before analysis.
www.nature.com/scientificreports/
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data in brain tissue from AD patients and rats with severe diabetes were similar with respect to their glucose, 
sorbitol and fructose content. Therefore, the brain in patients with AD presents an abnormality of glucose utili-
zation closely resembling that in the brain (the current study) and peripheral nervous tissue (sciatic nerve, dorsal 
root ganglia, and trigeminal ganglia) of the rats with severe diabetes51.
Our finding of elevated blood glucose, sorbitol and fructose in a patient with Braak Stage-II disease without 
clinical evidence of dementia is potentially significant, and suggests that metabolic disturbances in AD- brain 
may occur relatively early in disease progression. It was recently reported that acute hyperglycemia in young 
AD-model mice had increased Aβ production in the interstitial fluid, which was augmented in aged AD-mice 
with marked Aβ plaque pathology, identifying a mechanism by which systemic glucose elevation could damage 
brain cells52. However, in light of our current findings of marked elevations of brain glucose, sorbitol and fructose 
levels in AD without systemic elevation of glucose, direct toxicity caused by isolated intra-cerebral metabolite 
elevations could provide an alternative mechanism for neurodegeneration in AD.
How might elevated brain levels of glucose, sorbitol and fructose cause neurodegeneration? One potential 
mechanism is that glucose (an aldehyde) and fructose (a ketone) can attack macromolecules through their reac-
tive functional groups leading to AGE formation, as occurs in the diabetic complications29. Tissues in AD brain 
are known to be modified by N-epsilon-carboxymethyllysine (CML) formation9,53, which coordinates divalent 
copper9,13,54, localizing it to affected regions and thereby enhancing localized pro-oxidant stress55,56; consistent 
with this mechanism, copper homeostasis is evidently impaired in AD (summarized in)13. These mechanisms 
may well make similar contributions to AGE formation and downstream pathogenesis in AD.
Brain glucose uptake in AD is lower in severely affected regions and occurs early in disease development18. For 
example, using 2-[18F]fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET), it has been shown 
that there is diminished glucose uptake in the hippocampus, parietotemporal cortex and/or posterior cingulate 
cortex in: (i) individuals who are at genetic risk for fAD57,58; (ii) individuals with a history of AD59; as well as (iii) 
those who have mild or no cognitive impairment but eventually go on to develop AD19. The relevance of studies 
in fAD to those of sporadic AD are uncertain; there is thus an identified need for similar metabolomic and met-
allomic studies in suitable cohorts of fAD patients. Elevated intracellular glucose diminishes the trans-membrane 
gradient that drives facilitative glucose uptake via glucose transporters, so these findings in fAD are not incon-
sistent with the current results: however, levels of brain glucose and polyol pathway intermediates in fAD are 
currently unknown. The findings in (iii) indicate that impaired cerebral glucose uptake presages the development 
of (presumably sporadic) AD: these findings are consistent with elevated brain glucose as a key early aspect of 
pathogenesis.
Figure 3. Regional brain glucose (upper panel) and brain copper (μmol/dry kg; lower panel) levels in 
patients with AD (n = 7–9/region; red) and controls (n = 7–9; black). Overall mean ( ± 95% CI; Confidence 
Interval) wet-weight/dry-weight ratio was 5.6 (5.4–5.8). Overall mean brain-glucose levels were higher 
(P = 9.7 × 10−13) and brain copper values lower (P = 1.6 × 10−8) in cases than controls. Mean brain copper in 
AD trended lower in every region: CB (P < 0.0001); MCx (P = 0.021); SCx (P = 0.027); CG (P = 0.0079); MTG 
(P = 0.013); ENT (P = 0.0046); and HP (P = 0.070); and there was modest evidence that overall brain-copper 
and brain-glucose values were inversely correlated (P = 0.021) in AD-patients but not controls. Abbreviations: 
CB, cerebellum; CG, cingulate gyrus; ENT, entorhinal cortex; HP, hippocampus; MCx, motor cortex; MTG, 
middle temporal gyrus; SCx, sensory cortex.
www.nature.com/scientificreports/
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It has also been shown that, before neuronal dysfunction develops, mice heterozygous for GLUT1 (Slc2a1) 
at the BBB develop cerebral blood flow perfusion deficits and BBB breakdown that leads to vascular-mediated 
neurodegeneration40: the relevance of this study in engineered mice to our findings in human brain is uncertain, 
given that these authors did not report brain-glucose levels. Our own findings show that adult triple-mutant mice 
did not develop elevated brain glucose, and that patterns of sorbitol and fructose levels differed markedly from 
those in patients with AD; we therefore conclude that these mice may not reflect disturbances of glucose and the 
polyol pathway that occur in humans with Alzheimer’s dementia, although the proviso remains that the disease in 
these mice is highly region-specific and may not have generated the widespread dysregulation present in patients. 
Further studies in this and other transgenic models of AD may be indicated. Here we employed male transgenic 
mice, to avoid the increased metabolic variability which can occur in female mice and is attributable to effects 
of the estrus cycle, and in light of the similar prevalence of AD in male and female patients. Study of only male 
transgenic mice may have affected our results since Dr LaFerla, who developed this model, has recently reported 
that male triple-transgenic mice may not exhibit the phenotypic traits originally described (see: https://www.jax.
org/strain/004807). Prevalence of AD is similar in male and female patients, so the potential sexual dimorphism 
in this model may represent another difference between it and the human disease process. Further studies in 
this and other transgenic models of AD are therefore indicated in order to ascertain whether any of the available 
models might demonstrate defective glucose and polyol pathway regulation similar to that present in AD brain.
In glycolysis, hexokinase and phosphofructokinase catalyse reactions where ATP is the phosphate-group 
donor. Current results could be consistent with inefficient glucose utilization caused by impaired glycolysis and 
consequent elevation in polyol-pathway metabolites; consistent with this interpretation, for example, hippocam-
pal lactate was elevated by 2.6-fold in cases compared with controls; fold-values (case-control ratios) measured in 
other brain regions were as follows: EC, 0.5; MTG, 1.3; SCx, 3.4; MCx, 7.3; CG, 1.7; CB, 0.6; thus values in SCx and 
MCx showed apparent upward trends, although these were not significant, possibly due to the limited numbers in 
each group. Further study of lactate levels in larger numbers of cases and controls will be required to confirm and 
extend these data. Elevation of brain glucose and polyol-pathway intermediates might be explained by impaired 
ATP supply leading to diminished glycolysis, suppressing these ATP-requiring phosphorylation reactions, and 
could ultimately result from impaired TCA cycle function60. Additionally, in the physiological cerebral milieu, gly-
cogen provides a metabolically-active storage form of glucose in astrocytes61,62. Therefore, it is possible that some 
of the elevated free glucose we measured in AD brains could have been derived from increased rates of glycogen 
breakdown via glycogenolysis; alternatively, elevated glucose could mediate increased deposition of brain glyco-
gen or other forms of polymerized glucose63 such as metabolically-inactive, high-molecular-weight amylose that 
may be formed at the expense of glycogen in AD brains, thereby decreasing the pool of metabolically-accessible 
stored glucose63.
Elevated free glucose promotes glycation of macromolecules leading to formation of CML. Here, our finding of 
elevated brain glucose in AD provides a molecular explanation for previously-reported elevations of CML in AD 
brain9. PET-imaging studies in AD, where the rate-constant k2 is ~normal64, argue against substantively-elevated 
cytoplasmic free glucose available for retrograde transport into the extracellular space. PET findings are not 
inconsistent with the current findings, however, with respect to large elevations in tissue-glucose since it binds to 
macromolecules in a form releasable upon chemical extraction. For example, formation of Schiff-base (aldimine) 
linkages to proteins is the first step in a reversible pathway leading to CML formation65, reconciling published 
imaging results with elevated brain-glucose levels; additionally, fructose binds to proteins through an equivalent 
mechanism66.
Cells require a substantial, uninterrupted copper supply to maintain effective levels of metabolic-fuel uti-
lization and anti-oxidant defense67. Copper for support of fuel utilization is required particularly by the 
copper-enzymes cytochrome oxidase I (COI) and COII (both inner-membrane components of mitochondrial 
respiratory-chain complex IV), and for anti-oxidant defense by copper-enzymes superoxide dismutase 1 (SOD1, 
intracellular) and SOD3 (extracellular)21,68. Deficient enzyme-bound copper caused by defective cell-copper 
uptake impairs enzyme function that can cause metabolic sequelae including severe tissue damage21,69. The 
brain has particularly large copper requirements compared with most other organs, since it is very metaboli-
cally active70 and generates large amounts of reactive oxygen species, particularly superoxide anion that requires 
clearance by SOD1 and SOD3. In this context, our current findings of severely-elevated glucose coupled with 
markedly-deficient copper levels in AD brain are significant, particularly given that elevated CML levels are also 
widespread in AD brain9. CML directly links elevated tissue-glucose with low tissue-copper, since increased 
tissue-glucose levels drive CML-modification of collagen71, which inhibits cell-copper uptake by suppressing 
cell-membrane copper transport via copper transporter 121. A similar process occurs in diabetic heart, where car-
diac copper is deficient along with hyperglycemia and elevated coronary CML21, causing myocardial-copper defi-
ciency that mirrors the current findings in AD brain and causes defective copper supply to SOD1 and cytochrome 
c oxidase/complex IV13,21. There is substantive evidence that defective tissue-copper uptake is triggered by coordi-
nation of bioactive divalent copper to CML in collagen54. These findings provide a new and potentially reversible 
mechanism for the causation of brain damage in AD. Whether this mechanism can be targeted by pharmacolog-
ical intervention in AD remains to be determined.
This study has limitations. There is evidence that brain from significant numbers of aged but cognitively unim-
paired patients may display elevated Braak stages, not infrequently up to III-IV72,73, whereas by contrast, our 
group of 9 controls showed scores of 0-II. In several studies, Braak scores in the range of 0-II have been reported 
to occur in more than half of all cognitively-normal elderly persons73–75, so our sample may well be consistent 
with derivation from a similar population. Knopman et al. concluded that “the majority of individuals who are 
cognitively normal near the time of their death have minimal amounts of tau-positive neuritic pathology (that is, 
Braak stage < IV)”73. Cases at the more severe end of the pathologic spectrum (Braak stages III-IV) lacking Aβ 
plaques have been reportedly reported in 2–10% of brains in large autopsy series that included community-based 
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sampling75–77. Thus it is not entirely clear whether our control group is representative of the status of aged patients 
without dementia: larger follow-up studies will be required in clinic-based and community-based cohorts to 
avoid selection bias77 and thereby to better characterise the status of the polyol pathway in aged patients with and 
without varying degrees of cognitive impairment.
Despite the limited numbers (n = 9 cases and n = 9 controls), our findings in seven brain regions are statis-
tically robust; however, they require replication in other cohorts of AD patients, and also extension to subjects 
with preclinical AD, mild cognitive impairment (MCI), and fAD syndromes. Data from the single patient with 
preclinical AD reported here provide compelling, albeit preliminary data that similar metabolic perturbations 
might occur in other patients with preclinical disease, but this remains to be verified in suitable larger studies. 
Equivalent post-mortem metabolomic studies in preclinical AD, MCI, and fAD will require studies of suitable 
brain tissue from cohorts of patients with these conditions, which are likely to be challenging, and lie beyond the 
scope of the current study. We did not have the opportunity of performing ante-mortem assessments by MMSE or 
CDR scoring in the post-mortem study: this represents a limitation that will only be addressed once suitable brain 
tissue from post-mortem cohorts of patients who have previously been characterized by MMSE/CDR scoring are 
analyzed by suitable metabolomic methods. The current study does, however, open the field up to consideration 
of the roles played by elevations in brain glucose and polyol-pathway metabolites and associated copper defi-
ciency in the pathogenesis of AD.
In conclusion, we have shown here that free glucose is markedly elevated in AD brain, particularly in vulner-
able regions where elevated glucose may well be linked to copper deficiency and tissue-damage. Brain-sorbitol 
and brain-fructose levels are also elevated in AD brain, consistent with increased polyol-pathway flux, potentially 
caused by defective glucose utilization via glycolysis and/or the TCA-cycle. A further, mechanistically-related 
finding is that pan-cerebral brain-copper deficiency accompanies these glucose and polyol-pathway defects: 
elevated tissue-CML levels provide a molecular linkage between elevated brain glucose and copper deficiency. 
Impaired neuronal glucose utilization could play a major role in tissue-damage in AD, possibly via defective 
mitochondrial metabolism caused by deficient copper supply to COI and COII, leading to impaired function of 
cytochrome c oxidase78. These findings provide a clear molecular linkage between mechanisms of tissue damage 
in AD and T2D. The process by which elevated brain glucose is linked to defective cell-copper uptake and intra-
cellular transport to key copper proteins such as COI, COII, SOD1 and SOD3, may well provide a new target for 
diagnostic imaging or therapeutic intervention.
Methods
Ethics. All experiments were performed in accordance with relevant guidelines and regulations as stated 
below: the case-control study of post-mortem human brain was approved by the University of Auckland Human 
Participants Ethics Committee with informed consent from all families. The observational case-control study was 
performed under a protocol approved by the Leeds Teaching Hospitals NHS Trust Research Ethics Committee 
with informed consent from participants or families of patients.
The studies in the streptozotocin-induced rat model of diabetes and the triple-transgenic mouse model of 
AD were performed under UK Home Office Licenses, according to protocols approved by the University of 
Manchester Animal Welfare and Ethical Review Body (AWERB), and were consistent with the Animals (Scientific 
Procedures) Act 1986 and the ARRIVE guidelines.
Human brains: acquisition and analysis. Human brains were obtained from the New Zealand 
Neurological Foundation Human Brain Bank, University of Auckland79. Tissue quality was confirmed by demon-
stration of mRNA integrity (data not shown). Each brain was dissected under the supervision of neuroanato-
mists (JX, SP, HJW and RLMF), who accurately identified each region. Ante-mortem MMSE and CDR (Clinical 
Dementia Rating) examinations were not performed on patients enrolled in the study of post-mortem human 
brain tissue. Tissue was analyzed for metabolites (~50–800 Da) and copper: regions studied were entorhinal cor-
tex, hippocampus, middle temporal gyrus, cingulate gyrus, sensory cortex, motor cortex, and cerebellum: grey 
matter from each region was sampled as shown (Suppl. Fig. S1). Aliquots of 50 ± 5 mg were dissected from each 
region and stored at − 80 °C until analysis, and were otherwise treated as previously described4. Patients had 
ante-mortem evidence of clinical dementia, whereas controls did not. Controls were selected by matching for 
age, sex and PMD (Tables 1 and 2). A consultant neuropathologist diagnosed or excluded AD by applying the 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria28, and determined the neuropatho-
logical severity by assigning the Braak stage22 and amyloid load by applying the 2013 consensus National Institute 
on Aging–Alzheimer’s Association guidelines2 (Tables 1 and 2).
Data from one control participant with Braak Stage II disease. One control patient had neuro-
pathological findings consistent with AD (Braak Stage II; Table 2) and was therefore diagnosed with preclinical 
disease: this finding is consistent with the known frequency of asymptomatic AD in similarly-aged groups in the 
study population80. To assess the impact of this patient’s data on the overall outcome, the main statistical analysis 
was performed twice, first by retaining the corresponding patient’s data in the control group (Table 3) and then 
by performing a second analysis using the same methods but excluding this patient’s data only: the two analyses 
yielded equivalent results so this patient’s data have been retained in the control group, despite the presence of 
some of the metabolic changes observed in diagnosed AD cases.
Observational case-control study. Patients with memory disorder and control participants without 
cognitive impairment were recruited81 respectively through memory clinics in Leeds and Dewsbury (England), 
and the Leeds Family Health Services Authority day hospitals and elderly medicine outpatient clinics in the 
Leeds area. All were of European Caucasian background and gave written informed consent (consent from 
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relatives of the AD-patients was provided, where appropriate). Diagnosis of probable AD was made in accord-
ance with international diagnostic criteria (National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association Work Group: NINCDS-ADRDA)82. All partici-
pants underwent a standardised clinical evaluation: medical history, fasting plasma glucose (FPG) and HbA1c, 
and cognitive function assessment by MMSE. AD samples were refined by excluding the few patients with diag-
nosed T1D or T2D, including those on insulin, or others with significant co-morbidities. Samples were then 
selected from the whole-study population for whom required measurements (FPG, HbA1c) were available83. The 
resulting 42 AD-patients were then age- and gender-matched to 43 corresponding controls.
Analysis of rat brain. We employed a validated model of diabetes21 using 6-7 week-old male Wistar rats 
(n = 14), with body-weights of 220–250 g, maintained under a 12:12-h light:dark cycle and housed at 22 ± 2 °C 
and 60% humidity, with ad libitum access to standard rat chow (Special Diets Services, Dietex International, 
Essex, UK) and fresh water. Diabetes was induced (n = 7) by intraperitoneal injection of streptozotocin (55 mg/kg; 
Sigma Aldrich, Gillingham, UK) and diagnosed by blood-glucose levels of >15 mmol/l on two consecutive 
measurements21; non-diabetic control animals (n = 7) were age-matched littermates who received a single intra-
peritoneal injection of sodium-citrate buffer (vehicle) only. Eleven weeks after induction, we euthanized rats 
by terminal isoflurane anesthesia, excised brains, and stored them at − 80 °C until analysis. Whole brains were 
homogenized and sampled to yield 50 ± 5 mg (wet-weight) aliquots. Equivalent methods were used for analysis 
of mouse-brain tissue.
Transgenic mice: methods. Male triple transgenic (3xTgAD) mice expressing mutant PS1M146V, APPSwe, 
TauP301L, and control non-transgenic (non-Tg, 129/C57BL6) mice, were originally supplied by Frank LaFerla 
(Irvine, CA, USA)26 and an in-house colony established at the University of Manchester. All mice were kept in 
standard housing conditions (humidity 50–60%, temperature 21 ± 1 °C, 12:12 hour light-dark cycle) and given 
ad libitum access to standard rodent chow (Special Diets Services). At 13–14 months of age, non-Tg (n = 10) and 
3xTgAD (n = 10) were terminally anesthetized with 3-5% isoflurane (30% O2 and 70% N2O) and then transcar-
dially perfused with 0.9% saline. The brains were quickly removed, and one hemisphere was snap-frozen on dry 
ice and stored at − 80 °C until analysis.
Analytical methods. More detailed descriptions are given in the Supplementary Materials. Briefly, metabo-
lite levels were compared between cases and controls by gas chromatography mass spectrometry (GC-MS)-based 
metabolomics in wet-tissue24, copper was measured in dry-tissue by inductively-coupled-plasma mass spectrom-
etry (ICP-MS)25, and statistical analysis was performed as described in the Supplementary Materials. P-values 
of < 0.05 were considered significant.
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